Bonus Material-27_Khurana_COPD_2025

Pdf Summary

This comprehensive Pulmonary Board Review by Dr. Sandhya Khurana covers Chronic Obstructive Pulmonary Disease (COPD), emphasizing its definition, epidemiology, pathophysiology, diagnosis, management, and comorbidities. COPD is a heterogeneous lung disease marked by chronic respiratory symptoms and persistent airflow obstruction resulting from complex gene-environment interactions over a lifetime. Globally, it affects about 10.6% of the population (~480 million people), causing 3 million deaths annually, making it the third leading cause of death worldwide. Risk factors include tobacco smoke, biomass and outdoor pollution, occupational exposures, and genetic factors such as alpha-1 antitrypsin (AAT) deficiency.<br /><br />The lecture reviews COPD classification using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) system, which grades airflow limitation (FEV1-based) and symptom-exacerbation assessment (using mMRC, CAT, and BODE indices). The BODE score, incorporating BMI, airflow obstruction, dyspnea, and exercise capacity, predicts mortality more accurately than FEV1 alone.<br /><br />Treatment strategies involve pharmacologic and non-pharmacologic therapies. Bronchodilators remain central: long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) improve lung function, symptoms, and reduce exacerbations, with dual LAMA/LABA outperforming monotherapy. Inhaled corticosteroids (ICS), part of triple therapy (ICS/LABA/LAMA), further reduce exacerbations and mortality in selected patients though increase pneumonia risk. Emerging treatments include macrolide antibiotics, PDE4 inhibitors like roflumilast, and nebulized bronchodilators (e.g., ensifentrine). Biologic therapies are being evaluated with recent FDA approvals.<br /><br />Non-pharmacologic interventions include smoking cessation (which slows lung function decline and mortality), vaccinations, pulmonary rehabilitation (improving quality of life and reducing admissions), long-term oxygen therapy (for resting severe hypoxemia), and non-invasive ventilation (in stable hypercapnic COPD). Surgical options such as lung volume reduction surgery (LVRS) benefit patients with upper-lobe emphysema and low exercise capacity, while bronchoscopic lung volume reduction with endobronchial valves offers a less invasive alternative.<br /><br />COPD patients commonly have comorbidities including cardiovascular disease, osteoporosis, metabolic syndrome, GERD, and obstructive sleep apnea, which affect prognosis. Exacerbations, often triggered by infections, worsen lung function and increase mortality risk; prompt management includes bronchodilators, corticosteroids, antibiotics if indicated, and non-invasive ventilation.<br /><br />In summary, COPD is a preventable, complex disease requiring tailored therapies informed by severity, exacerbation risk, and patient characteristics. Advances in pharmacological and interventional treatments aim to improve survival, symptom control, and quality of life.

Meta Tag

Concept Chronic Obstructive Pulmonary Disease

Concept Acute Exacerbation

Concept GOLD Stage

Concept Spirometry

Concept Bronchodilator

Keywords

COPD

Chronic Obstructive Pulmonary Disease

GOLD classification

LAMA LABA therapy

triple inhaler therapy

alpha-1 antitrypsin deficiency

pulmonary rehabilitation

long-term oxygen therapy

lung volume reduction surgery

COPD exacerbations

Chronic Obstructive Pulmonary Disease

Acute Exacerbation

GOLD Stage

Spirometry

Bronchodilator

COPD